Precisis AG has closed its next financing round in Q2/2017. Apart from the original group of shareholders that has remained unchanged for many years, three further private investors have now bought into Precisis AG. In view of the successful technological development of its neurostimulation device EASEE®, the latest capital increase should be sufficient to secure the clinical phase.
“Our origins lie in neurosurgery, our incentive is individualised medical technology. As an innovative company, we have set ourselves the goal of treating functional cerebral diseases with micro-invasive, intelligent systems,” is how the CEO Dr. med. Angela Liedler describes the mandate for action of Precisis AG.
Funds from capital increase to be used for the EASEE® clinical trial
Since 2014, Precisis AG has been developing an easy-to-use device for the targeted therapy of cerebral diseases that originate in the superficial areas of the brain such as focal epilepsy. The successful finalisation of the technological development phase now paves the way for a first-in-human clinical trial.
The funds from the capital increase will be used to gather the first clinical data from patients and to prepare the market approval of EASEE®.